retatrutide side effects clinical trials 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide clinical trial done! Now

CVS Caremarks decision to remove Zepbound was not based on patient outcomes

Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

The Lancet and Nature Communications data suggest this is a real pharmacological effect rather than a reporting artifact

A major antioxidant involved in reducing oxidative stress, enhancing metabolic detoxification, and regulating the immune system, glutathione levels were found to have skyrocketed in metastatic cancer cells that invaded the lung

So, I think it will absolutely become standard in GLP 1s